Literature DB >> 2901127

Single-dose kinetics of the neuroleptic drug perazine in psychotic patients.

U Breyer-Pfaff1, K Nill, H W Schied, H J Gaertner, H Giedke.   

Abstract

Eight male and two female unmedicated psychotic patients received 100 mg perazine orally and seven blood samples were taken within 25 h. Plasma levels of perazine and its demethylated metabolite were analyzed by HPLC with electrochemical detection. They exhibited large interindividual variations, with maximal concentrations as well as AUC values of perazine differing more than 10-fold. From the decay of plasma levels during the last 12-18 h half-lives were estimated to be between 7.5 and 10 h; they did not correlate with AUC. There was a significant positive correlation between AUC and age. Desmethylperazine was consistently present at lower concentrations than the parent drug during the first 12 h.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901127     DOI: 10.1007/bf00181950

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup.

Authors:  S G Dahl; R E Strandjord; S Sigfusson
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

2.  Perazine, chlorpromazine and imipramine as inducers of microsomal drug metabolism.

Authors:  U Breyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

3.  Urinary metabolites of 10-(3'-(4"-methyl-piperazinyl)-propyl)-phenothiazine (perazine) in psychiatric patients. II. Individual metabolite patterns and their changes in the course of treatment.

Authors:  K Kanig; U Breyer
Journal:  Psychopharmacologia       Date:  1969

4.  Factors affecting chlorpromazine plasma levels in psychiatric patients.

Authors:  S H Curry; J M Davis; D S Janowsky; J H Marshall
Journal:  Arch Gen Psychiatry       Date:  1970-03

5.  [Metabolism and excretion of the neuroleptic drug perazine in healthy volunteers].

Authors:  J Schley; E Riedel; B Müller-Oerlinghausen
Journal:  Int Pharmacopsychiatry       Date:  1981

6.  Prolonged pharmacologic activity of neuroleptic drugs.

Authors:  J W Hubbard; D Ganes; K K Midha
Journal:  Arch Gen Psychiatry       Date:  1987-01

7.  Pharmacokinetics of chlorpromazine after single and chronic dosage.

Authors:  S G Dahl; R E Strandjord
Journal:  Clin Pharmacol Ther       Date:  1977-04       Impact factor: 6.875

8.  Kinetics of oral trifluoperazine disposition in man.

Authors:  K K Midha; E D Korchinski; R K Verbeeck; R M Roscoe; E M Hawes; J K Cooper; G McKay
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

9.  Clinical pharmacokinetic studies of perphenazine.

Authors:  C Eggert Hansen; T Rosted Christensen; J Elley; L Bolvig Hansen; P Kragh-Sorensen; N E Larsen; J Naestoft; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

10.  Test dose response in schizophrenia: chlorpromazine blood and saliva levels.

Authors:  P R May; T Van Putten; D J Jenden; A K Cho
Journal:  Arch Gen Psychiatry       Date:  1978-09
View more
  1 in total

1.  [Expanding therapeutic reference ranges using dose-related reference ranges].

Authors:  E Haen; C Greiner; W Bader; M Wittmann
Journal:  Nervenarzt       Date:  2008-05       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.